Skip to content
BIO 2025: The urgent need to address AMR and cancer
As antimicrobial resistance (AMR) continues to threaten global public health, its impact on ...
Read More
BIO expert explains patents at DOJ and FTC listening session
Patents enable the innovation that produces new lifesaving treatments while ensuring a competitive ...
Read More
A conversation with Fritz Bittenbender, new BIO Board Chair
The exciting new developments we’re seeing in biotechnology must be supported by equally ...
Read More
Onerous reporting requirements crushing small biotechs, BIO Board member testifies
Even if they aren’t making revenue, small biotechs can face onerous reporting requirements ...
Read More
BIO 2025: The innovation race vs. the regulatory pace
We often talk about the exciting jumps in technology and innovation that improve ...
Read More
BIO 2025: The world can’t wait – it needs to collaborate
Biotech is a global business, and we’re better for it, said experts at ...
Read More
EDITORS' CHOICE
A conversation with Fritz Bittenbender, new BIO Board Chair
The exciting new developments we’re seeing in biotechnology must be supported by equally innovative policy, according to Fritz Bittenbender, the new Chair of the Board ...
Read More
LATEST NEWS
BIO Events
BIO 2025: The urgent need to address AMR and cancer
As antimicrobial resistance (AMR) continues to threaten global public health, its impact on cancer patients is a growing, often overlooked crisis. Patients with cancer are ...
Federal Policy
BIO expert explains patents at DOJ and FTC listening session
Patents enable the innovation that produces new lifesaving treatments while ensuring a competitive market, the top IP expert for the Biotechnology Innovation Organization (BIO) told ...
BIO Events
A conversation with Fritz Bittenbender, new BIO Board Chair
The exciting new developments we’re seeing in biotechnology must be supported by equally innovative policy, according to Fritz Bittenbender, the new Chair of the Board ...
BIO's View
Onerous reporting requirements crushing small biotechs, BIO Board member testifies
Even if they aren’t making revenue, small biotechs can face onerous reporting requirements that cost $1 million or more, cutting into the firms’ ability to ...
BIO Events
BIO 2025: The innovation race vs. the regulatory pace
We often talk about the exciting jumps in technology and innovation that improve and save lives. What is less frequently discussed is how regulation has ...
HEALTH
Welcome, John F. Crowley!
Get to know John F. Crowley, the new President and CEO of the Biotechnology Innovation Organization (BIO), in our exclusive interview.
Federal Policy
State Policy
BIO 2025: A few highlights from Day 2
George W. Bush, 43rd President of the United States, headlined Tuesday’s mainstage with an exclusive conversation with Biotechnology Innovation Organization ...
Read More
International
Bio's View
Onerous reporting requirements crushing small biotechs, BIO Board member testifies
Even if they aren’t making revenue, small biotechs can face onerous reporting requirements that cost $1 million or more, cutting ...
Read More
